Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: A multicenter noncomparative interventional case series

Ophthalmology

Volumn 112, Issue 5, 2005, Pages 764-770

  Nussenblatt, Robert B ^a   Peterson, Jan S ^b   Foster, C Stephen ^c   Rao, Narsing A ^d   See, Robert F ^d   Letko, Eric ^c   Buggage, Ronald R ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b EMMES CORPORATION   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CHLORAMPHENICOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; GLATIRAMER; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC RETINOPATHY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; ENTERITIS; EYE INFLAMMATION; FEMALE; HORDEOLUM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LIVER TOXICITY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PAIN; PAPILLOMA; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; SUPERINFECTION; TIME SERIES ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DRUG EVALUATION; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PANUVEITIS; PILOT PROJECTS; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; SAFETY; UVEITIS, INTERMEDIATE; UVEITIS, POSTERIOR; VISUAL ACUITY;

EID: 18244401345     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2004.12.034     Document Type: Article

References (19)

1. R.B. Nussenblatt The natural history of uveitis Int Ophthalmol 14 1990 303 308
2. D.C. Gritz, I.G. Wong Incidence and prevalence of uveitis in Northern California the Northern California Epidemiology of Uveitis Study Ophthalmology 111 2004 491 500
3. D.A. Jabs, J.T. Rosenbaum, C.S. Foster Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders recommendations of an expert panel Am J Ophthalmol 130 2000 492 513
4. R.R. Caspi, F.G. Roberge, C.G. McAllister T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat J Immunol 136 1986 928 933
5. R.R. Caspi Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis Int Rev Immunol 21 2002 197 208
6. M.S. Lacomba, C.M. Martin, R.R. Chamond Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis Arch Ophthalmol 118 2000 768 772
7. A.H. Rahi, A. Al-Kaff Cytokine profile in uveitis a point prevalence study R.B. Nussenblatt S.M. Whitcup R.R. Caspi I. Gery Advances in Ocular Immunology 1994 Elsevier Amsterdam 369 372 Proceedings of the 6th International Symposium on the Immunology and Immunopathology of the Eye. Bethesda, Md, 1994.
8. M.H. Reed, M.E. Shapiro, T.B. Strom Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody Transplantation 47 1989 55 59
9. P.S. Brown Jr, G.L. Parenteau, F.M. Dirbas Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival Proc Natl Acad Sci U S A 88 1991 2663 2667
10. P. Herve, J. Wijdenes, J.P. Bergerat Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10) Blood 75 1990 1017 1023
11. C. Queen, W.P. Schneider, H.E. Selick A humanized antibody that binds to the interleukin 2 receptor Proc Natl Acad Sci U S A 86 1989 10029 10033
12. R.B. Nussenblatt, E. Fortin, R. Schiffman Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb a phase I/II clinical trial Proc Natl Acad Sci U S A 96 1999 7462 7466
13. R.B. Nussenblatt, D.J.S. Thompson, Z. Li Humanized anti-interleukin-2 (IL-2) receptor alpha therapy long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration J Autoimmun 21 2003 283 293
14. G.N. Papaliodis, D. Chu, C.S. Foster Treatment of ocular inflammatory disorders with daclizumab Ophthalmology 110 2003 786 789
15. H.P. Brok, J.M. Tekoppele, J. Hakimi Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys Clin Exp Immunol 124 2001 134 141
16. G. Van Assche, I. Dalle, M. Noman A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis Am J Gastroenterol 98 2003 369 376
17. R.B. Nussenblatt, S.M. Whitcup, A.G. Palestine Uveitis Fundamentals and Clinical Practice 2nd ed. 1996 Mosby St. Louis
18. S.J. Kimura, P. Thygeson, M.J. Hogan Signs and symptoms of uveitis. II. Classification of the posterior manifestations of uveitis Am J Ophthalmol 47 1959 171 176
19. R.B. Nussenblatt, A.G. Palestine, C.C. Chan, F. Roberge Standardization of vitreal inflammatory activity in intermediate and posterior uveitis Ophthalmology 92 1985 467 471